Omeprazole Articles
Klaricid Approved For HP Eradication In UK
13 March 1995
Dutch Govt Has Mistaken Impression Of Drug Prices
13 March 1995
Astra Pretax Profit Rockets 23%, Fuelled By Losec
27 February 1995
Eli Lilly Publishes Letter
27 February 1995
Glaxo Interim Profits Up 10% On 2% Sales Rise
13 February 1995
New Chemical Entities Round-Up For 1994
6 February 1995
Omeprazole News
23 January 1995
Abbott Files For H pylori Eradication
9 January 1995
Glaxo Files For Ranitidine Bismuth Citrate Approval
2 January 1995
European Stock Comment
19 December 1994
EUROPE STOCK COMMENT
12 December 1994
Losec For GERD Maintenance In USA
12 December 1994
Astra Updates On Its R&D Pipeline
5 December 1994
Helicobacter pylori Eradication Halts Gastric Cancer
28 November 1994
Zantac Approved For Eradication Therapy In UK
21 November 1994
Strong Sales And Profits Growth At Astra
21 November 1994
Losec Tops Anti-Ulcerant Sales In UK
7 November 1994
Astra Merck: New Stand-Alone Company
7 November 1994
EUROPEAN STOCK COMMENT
7 November 1994
Abbott's AIDS Drug In Phase I/II Studies
24 October 1994
Merck Warned By FDA
10 October 1994
Eradication Therapy For Helicobacter Pylori
10 October 1994
European Stock Comment
12 September 1994
Strong Performance By Astra In First Half
5 September 1994
France Cuts Drug Prices, Bans Promo Campaigns
5 September 1994
German Authorities Probe Two Schering AG Drugs
22 August 1994
More On Injectable Losec Suspension IN Germany
15 August 1994
Benefits From PBM/MPC Acquisitions Assessed
15 August 1994
NGF IN ALZHEIMERS
8 August 1994
Losec Cleared OverSafety Queries
1 August 1994
FDA Warns Lilly Over Axid Claims
1 August 1994
ASTA/MERCK AND ABBOTT COLLABORATION
4 July 1994
FIRST CLINICAL DATA FOR GLAXO'S GR122311X
6 June 1994
ASTRA AND TAKEDA SETTLEMENT
30 May 1994
STRONG FIRST QTR FOR ASTRA
23 May 1994
ASTRA RESPONDS TO KOREAN OMEPRAZOLE
16 May 1994
ASTRA DEFENDS LOSEC SAFETY
9 May 1994
MERCK & CO POSTS 10% PR0FIT RISE
25 April 1994
ZOTON OFFERS BENEFITS OVER H2S & OMEPRAZOLE
18 April 1994
ISRAELI PHARMA MARKET STAGNANT IN 1993
18 April 1994
EUROPEAN STOCK COMMENT
11 April 1994
FUTURE LOOKS ROSY FOR LOSEC H PYLORI COMBO
4 April 1994
ASTRA'S SHARE PRICE TAKES TEMPORARY DIP
4 April 1994
EUROPEAN STOCK COMMENT
21 March 1994
UK INDUSTRY REPORT ON "BRIBERY" CHARGES
21 March 1994
EUROPEAN STOCK COMMENT
14 March 1994
UK PRESCRIBING STUDY "WOULD RAISE COSTS"
14 March 1994
ASTRA DEFENDS LOSEC POSITION IN GERMANY
14 March 1994
STRONG 1993 RESULTS POSTED BY ASTRA
7 March 1994
GYNECOMASTIA WITH ANTIULCERANTS
28 February 1994
EUROPEAN STOCK COMMENT
28 February 1994
EISAI FILES NDA FOR PROTON PUMP DRUG
28 February 1994
SWEDISH PHARMA MARKET GROWTH SLOWDOWN
28 February 1994
NIH ISSUES CONSENSUS STATEMENT ON H PYLORI
14 February 1994
BIAXIN PUT FORWARD FOR ULCER THERAPY
14 February 1994
EUROPEAN STOCK COMMENT
14 February 1994
ASTRA IN CHINESE JOINT VENTURE
7 February 1994
WINNERS AND LOSERS IN GLOBAL PHARMA INDUSTRY
31 January 1994
ASTRA RECEIVES APPROVAL
24 January 1994
LIKELY IMPACT ON DRUG FIRMS OF ITALIAN REFORMS
17 January 1994
EXPANDING PHARMA MARKET IN TURKEY
10 January 1994
DIVERSIFICATION NOT THE PATH FOR GLAXO
13 December 1993
WORLD MARKETS FOR CNS AND GASTROINTESTINALS
13 December 1993
ALTANA PLANS DRUG INNOVATION OFFENSIVE
13 December 1993
ASTRA BROADENS RESEARCH BASE
29 November 1993
EUROPEAN STOCK COMMENT
22 November 1993
POWERFUL GAINS AS ASTRA STRENGTHENS
22 November 1993
BRIBERY AND RIVALRY IN PHARMA SECTOR
22 November 1993
ASTRA'S ROXIAM HITS TOXICITY TROUBLE
8 November 1993
US 3rd QTR RESULTS MIXED AS DRUG IND CUTS BACK
25 October 1993
ASTRA LAUNCHES 40mg LOSEC TABLET
11 October 1993
TOKYO TANABE TO CODEVELOP TU-199
11 October 1993
ABBOTT'S HYTRIN GETS BPH APPROVAL IN USA
11 October 1993
ULCER DRUG MARKET DECLINE FORECAST
4 October 1993
OMEPRAZOLE ON QUEBEC'S LIMITED LIST
13 September 1993
STRONG PERFORMANCE FROM GLAXO, AND ZANTAC
13 September 1993
ASTRA STRONG IN 1st HALF 1993
6 September 1993
US DRUGSTORE AUDIT DATA FOR JULY
6 September 1993
MERCK HITS TRIGGER FOR ASTRA BUSINESS
16 August 1993
ASTRA DEFENDS LOSEC PATENT RIGHTS
2 August 1993
GASTROENTEROLOGY CONFERENCE REPORT
26 July 1993
GROWTH AHEAD ALTANA WITH REBOUND IN 1994
7 June 1993
PRETAX PROFITS SOAR AT ASTRA
24 May 1993
TOKYO STOCK COMMENT
17 May 1993
LONDON STOCK COMMENT
12 April 1993
NEW DATA ON LOSEC IN ULCER RELAPSE
12 April 1993
PRICE FLEXIBILITY AND THE DRUG INDUSTRY
12 April 1993
JOB CUTS AND EARNINGS WARNING FROM MERCK
5 April 1993
SWEDEN'S PHARMA MARKET IN 1992
5 April 1993
GLOBAL SALES OF H2 BLOCKERS TO DECLINE?
1 March 1993
PRETAX AND EPS SOAR AT ASTRA IN 1992
1 March 1993
MERCK CANADA MOVES TO WARD OFF COMPETITION
1 March 1993
ASTRA'S EXPECTED GROWTH AT 25% PER YEAR
22 February 1993
GLAXO TO FILE FOR OTC ZANTAC IN 1994?
1 February 1993
NEW CHEMICAL ENTITIES LAUNCHED IN 1992
1 February 1993
LONG-TERM USE OF CISAPRIDE IN UK
18 January 1993
GLAXO AND LILLY'S ULCER DRUGS OFF MEDI-CAL
18 January 1993
LOSEC SALES TO TOP $1 BILLION IN 1992
21 December 1992
LANSOPRAZOLE READY FOR LAUNCH
14 December 1992
MERCK & CO EARNINGS ESTIMATES LOWERED
14 December 1992
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
